Efficacy of new ruthenium complexes against chemically induced autochthonous colorectal carcinoma in rats.

No abstract is available for this paper.

• Publication year

  1989

• Venue

  Anticancer Research

• Publication date

  1989-05-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  PMID 2764521
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Comparative antitumor activity of ruthenium derivatives with 5′-deoxy-5-fluorouridine in chemically induced colorectal tumors in SD rats

  2004cited by this paper
• Efficacy of β-diketonato complexes of titanium, zirconium, and hafnium against chemically induced autochthonous colonic tumors in rats

  2004cited by this paper
• Antitumor activity of cis-dihalogenobis(1-phenyl-1,3-butanedionato)titanium(IV) compounds

  2004cited by this paper
• Synthesis and antitumor activity of triazolium-bis(triazole)-tetrachlororuthenate (III) and bistriazolium-triazolepentachlororuthenate (III). Two representatives of a new class of inorganic antitumor agents.

  1987cited by this paper
• Paradoxical effect of dichlorobis(1-phenylbutane-1,3-dionato)molybdenum (IV), (Mo(bzac)2Cl2 on the growth of autochthonous chemically induced colorectal tumors in SD rats.

  1987cited by this paper
• Antitumor activity of imidazolium-bisimidazole-tetrachlororuthenate (III)

  1986cited by this paper
• Preclinical evaluation of dichlorobis(1-phenylbutane-1,3-dionato)titanium (IV) and budotitane. Two representatives of the new class of antitumor-active bis-beta-diketonato metal complexes.

  1986cited by this paper
• Autochthonous, acetoxymethylmethylnitrosamine-induced colorectal cancer in rats: a useful tool in selecting new active antineoplastic compounds?

  1986cited by this paper
• Antitumor activity of 1.3-diketonato zirconium (IV) and hafnium (IV) complexes.

  1985cited by this paper
• Antitumor activity of phenyl substituted dihalogenobis (1-phenyl-1,3-butanedionato)titanium (IV) compounds.

  1985cited by this paper
• Antitumor activity of cis-dihalogenobis(1-phenyl-1,3-butanedionato) titanium(IV) compounds against Walker 256 carcinosarcoma. A new class of antineoplastic agents.

  1982cited by this paper
• Endoscopic diagnosis of chemically induced autochthonous colonic tumors in rats.

  1981cited by this paper
• Evaluation of endoscopic examination of colon tumors in rats

  1975cited by this paper

• Ruthenium(III) and (II) complexes containing pyridine moiety: synthesis, crystal structure and in vitro biological evaluation

  2022cites this paper
• Chemistry towards Biology—Instruct: Snapshot

  2022cites this paper
• Highly Cytotoxic Osmium(II) Compounds and Their Ruthenium(II) Analogues Targeting Ovarian Carcinoma Cell Lines and Evading Cisplatin Resistance Mechanisms

  2022cites this paper
• Half sandwiched RutheniumII complexes: En Route towards the targeted delivery by Human Serum Albumin (HSA)

  2021cites this paper
• Die Wechselwirkung mit ribosomalen Proteinen begleitet die Stressinduktion des Wirkstoffkandidaten BOLD‐100/KP1339 im endoplasmatischen Retikulum

  2021cites this paper
• Proteomic analysis of the S. cerevisiae response to the anticancer ruthenium complex KP1019.

  2020cites this paper
• DDDT_A_275007 5375..5392

  2020cites this paper
• Interaction with Ribosomal Proteins Accompanies Stress Induction of the Anticancer Metallodrug BOLD‐100/KP1339 in the Endoplasmic Reticulum

  2020cites this paper
• Ruthenium Complexes as Anticancer Agents: A Brief History and Perspectives

  2020cites this paper
• Ruthenium(III) complexes with imidazole ligands that modulate the aggregation of the amyloid-β peptide via hydrophobic interactions.

  2020cites this paper
• Synthesis, chemical characterization, PARP inhibition, DNA binding and cellular uptake of novel ruthenium(II)-arene complexes bearing benzamide derivatives in human breast cancer cells.

  2020cites this paper
• Cytotoxic RuII-p-cymene complexes of an anthraimidazoledione: halide dependent solution stability, reactivity and resistance to hypoxia deactivation.

  2019cites this paper
• Progress in the Utilisation of Organometallic Compounds in the Development of Cancer Drugs

  2019cites this paper
• Prodrugs activated by implantable microsystems

  2019cites this paper
• NAMI-A and KP1019/1339, Two Iconic Ruthenium Anticancer Drug Candidates Face-to-Face: A Case Story in Medicinal Inorganic Chemistry

  2019cites this paper
• Structure-activity relationships for ruthenium and osmium anticancer agents - towards clinical development.

  2018cites this paper
• Synthesis and Characterization of trans-Dichlorotetrakis(imidazole)cobalt(III) Chloride: A New Cobalt(III) Coordination Complex with Potential Prodrug Properties

  2018influential citation
• RuIII Complexes for Anticancer Therapy: The Importance of Being Nucleolipidic

  2017cites this paper
• Half-sandwich ruthenium(ii) complexes containing N^N-chelated imino-pyridyl ligands that are selectively toxic to cancer cells.

  2017cites this paper
• Neutron activation increases activity of ruthenium-based complexes and induces cell death in glioma cells independent of p53 tumor suppressor gene

  2017cites this paper
• Design Aspects of Ruthenium Complexes as DNA Probes and Therapeutic Agents

  2017cites this paper
• A Ruthenium(II) Polypyridyl Nucleoside as a Potential Photodynamic Therapy Agent

  2016cites this paper
• Metal Based Compounds, Modulators of Na, K-ATPase with Anticancer Activity

  2016cites this paper
• Chapter 3 In vivo anti-tumor activity of the organometallic ruthenium ( II )-arene complex [ Ru ( ɳ 6p-cymene ) Cl 2 ( pta ) ] ( RAPTA-C ) in human ovarian and colorectal carcinomas

  2015cites this paper
• Cadmium-coordinated supramolecule suppresses tumor growth of T-cell leukemia in mice

  2015cites this paper
• A Dimetallic Osmium(II) Complex as a Potential Phototherapeutic Agent: Binding and Photocleavage Studies with Plasmid DNA

  2015cites this paper
• DNA Damage Response Checkpoint Activation Drives KP1019 Dependent Pre-Anaphase Cell Cycle Delay in S. cerevisiae

  2015cites this paper
• Use of high-performance liquid chromatography–tandem electrospray ionization mass spectrometry to assess the speciation of a ruthenium(III) anticancer drug in the cytosol of cancer cells

  2015cites this paper
• Luminescent ruthenium complexes for theranostic applications.

  2014cites this paper
• Benzyl-substituted metallocarbene antibiotics and anticancer drugs.

  2014cites this paper
• Modulation of Activity of Known Cytotoxic Ruthenium(III) Compound (KP418) with Hampered Transmembrane Transport in Electrochemotherapy In Vitro and In Vivo

  2014cites this paper
• Anti‐cancer drug KP1019 modulates epigenetics and induces DNA damage response in Saccharomyces cerevisiae

  2014cites this paper
• In vivo anti-tumor activity of the organometallic ruthenium(II)-arene complex [Ru(η6-p-cymene)Cl2(pta)] (RAPTA-C) in human ovarian and colorectal carcinomas

  2014cites this paper
• Anti-cancer drug KP1019 induces Hog1 phosphorylation and protein ubiquitylation in Saccharomyces cerevisiae.

  2014cites this paper
• Striking Difference in Antiproliferative Activity of Ruthenium- and Osmium-Nitrosyl Complexes with Azole Heterocycles

  2013cites this paper
• On the Electronic Structure of mer,trans‐[RuCl3(1H‐indazole)2(NO)], a Hypothetical Metabolite of the Antitumor Drug Candidate KP1019: An Experimental and DFT Study

  2013cites this paper
• Analysis of the cytotoxic effects of ruthenium–ketoconazole and ruthenium–clotrimazole complexes on cancer cells

  2013cites this paper
• THE EFFECTS OF SOME PHENANTHROLINE RUTHENIUM (II) COMPLEXES ON A549 CELL PROLIFERATION

  2013cites this paper
• Transferrin serves as a mediator to deliver organometallic ruthenium(II) anticancer complexes into cells.

  2013cites this paper
• Increasing the bioavailability of Ru(III) anticancer complexes through hydrophobic albumin interactions.

  2013cites this paper
• The Anticancer Ruthenium Complex KP1019 Induces DNA Damage, Leading to Cell Cycle Delay and Cell Death in Saccharomyces cerevisiae

  2013cites this paper
• Ruthenium Complex KP 1019 Induces DNA Damage , Leading to Cell Cycle Delay and Cell Death in Saccharomyces cerevisiae

  2012cites this paper
• Approaching tumour therapy beyond platinum drugs: status of the art and perspectives of ruthenium drug candidates.

  2012cites this paper
• Recent progress and future potential for metal complexes as anticancer drugs targeting G-quadruplex DNA.

  2012cites this paper
• LC- and CZE-ICP-MS approaches for the in vivo analysis of the anticancer drug candidate sodium trans-[tetrachloridobis(1H-indazole)ruthenate(III)] (KP1339) in mouse plasma.

  2011cites this paper
• Polynuclear ruthenium, osmium and gold complexes. The quest for innovative anticancer chemotherapeutics.

  2011cites this paper
• Ruthenium and Other Non‐Platinum Anticancer Compounds

  2011cites this paper
• Ruthenium(II) complexes: Cellular uptake, cytotoxicity, DNA-binding, photocleavage and antioxidant activity studies

  2011cites this paper
• Arene-Ru(II)-chloroquine complexes interact with DNA, induce apoptosis on human lymphoid cell lines and display low toxicity to normal mammalian cells.

  2010cites this paper
• The influence of electroporation on cytotoxicity of anticancer ruthenium(III) complex KP1339 in vitro and in vivo.

  2010cites this paper
• The Ruthenium Complex cis-(Dichloro)tetraammineruthenium(III) Chloride Presents Selective Cytotoxicity Against Murine B Cell Lymphoma (A-20), Murine Ascitic Sarcoma 180 (S-180), Human Breast Adenocarcinoma (SK-BR-3), and Human T Cell Leukemia (Jurkat) Tumor Cell Lines

  2010cites this paper
• In vitro Ruthenation of Human Breast Cancer Suppressor Gene 1 (BRCA1) by the Antimetastasis Compound RAPTA‐C and Its Analogue CarboRAPTA‐C

  2010cites this paper
• Anticancer activities of the ruthenium carboxylato, amido and pyridine complexes.

  2010cites this paper
• New platinum and ruthenium complexes--the latest class of potential chemotherapeutic drugs--a review of recent developments in the field.

  2009cites this paper
• Unusual DNA binding modes for metal anticancer complexes.

  2009cites this paper
• Pharmacokinetic study of sodium trans[tetrachlorobis(1H-indazole)-ruthenate (III)]/-indazole hydrochloride (1:1.1) (FFC14A) in patients with solid tumors.

  2009cites this paper
• Electronic structural investigations of ruthenium compounds and anticancer prodrugs

  2009cites this paper
• The ruthenium(II)–arene compound RAPTA-C induces apoptosis in EAC cells through mitochondrial and p53–JNK pathways

  2008cites this paper
• Evaluation of in vitro models for detection of hepatocyte toxicity induced by anti-cancer drugs

  2008cites this paper
• Electron-transfer activated metal-based anticancer drugs

  2008cites this paper
• Synthesis and reactivity of the aquation product of the antitumor complex trans-[Ru(III)Cl4(indazole)2]-.

  2008cites this paper
• KP1019, A New Redox‐Active Anticancer Agent – Preclinical Development and Results of a Clinical Phase I Study in Tumor Patients

  2008cites this paper
• Antitumour metal compounds: more than theme and variations.

  2008cites this paper
• Synthesis and spectroscopic studies of some halogen-dimethylsulphoxide/tetramethylenesulphoxide-ruthenium(II) and ruthenium(III) complexes with 2-aminobenzimidazole

  2007cites this paper
• Ruthenium(III) maltolato-nitroimidazole complexes: synthesis and biological activity.

  2006cites this paper
• Redox behavior of tumor-inhibiting ruthenium(III) complexes and effects of physiological reductants on their binding to GMP.

  2006cites this paper
• Anti-tumour activity in non-small cell lung cancer models and toxicity profiles for novel ruthenium(II) based organo-metallic compounds.

  2006cites this paper
• Ruthenium complexes as anticancer agents.

  2006cites this paper
• DNA binding mode of ruthenium complexes and relationship to tumor cell toxicity.

  2006cites this paper
• From bench to bedside--preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019 or FFC14A).

  2006cites this paper
• Heterocyclic complexes of ruthenium(III) induce apoptosis in colorectal carcinoma cells

  2005cites this paper
• Redox-active antineoplastic ruthenium complexes with indazole: correlation of in vitro potency and reduction potential.

  2005cites this paper
• Antineoplastic activity of three ruthenium derivatives against chemically induced colorectal carcinoma in rats

  2005cites this paper
• Tuning of redox properties for the design of ruthenium anticancer drugs: part 2. Syntheses, crystal structures, and electrochemistry of potentially antitumor [Ru III/II Cl6-n(Azole)n]z(n = 3, 4, 6) complexes.

  2005cites this paper
• The heterocyclic ruthenium(III) complex KP1019 (FFC14A) causes DNA damage and oxidative stress in colorectal tumor cells.

  2005cites this paper
• Activity of two platinum-linked phosphonic acids against autochthonous rat colorectal cancer as well as in two human colon-cancer cell lines

  2004cites this paper
• In vitro evaluation of platinum, titanium and ruthenium metal complexes in cisplatin-sensitive and-resistant rat ovarian tumors

  2004cites this paper
• Recent developments in the field of tumor-inhibiting metal complexes.

  2003cites this paper
• Synthesis, X-ray diffraction structures, spectroscopic properties, and in vitro antitumor activity of isomeric (1H-1,2,4-triazole)Ru(III) complexes.

  2003cites this paper
• Rhodium and its compounds as potential agents in cancer treatment.

  2002cites this paper
• In vitro and in vivo activity and cross resistance profiles of novel ruthenium (II) organometallic arene complexes in human ovarian cancer

  2002cites this paper
• Ruthenium-based compounds and tumour growth control (review).

  2000cites this paper
• Non-Platinum Antitumor Compounds

  1999cites this paper
• Metallopharmaceuticals I

  1999cites this paper
• Comparative nephrotoxicity of some antitumour‐active platinum and ruthenium complexes in rats

  1998cites this paper
• Preclinical activity of trans-indazolium[tetrachlorobisindazoleruthenate(III)] (NSC 666158; IndCR; KP 1019) against tumour colony-forming units and haematopoietic progenitor cells.

  1997cites this paper
• Interactions of metallopharmaceuticals with DNA.

  1996cites this paper
• Comparison of the Antiproliferative Activity of Two Antitumour Ruthenium(III) Complexes With Their Apotransferrin and Transferrin-Bound Forms in a Human Colon Cancer Cell Line

  1996cites this paper
• Synergistic antitumor interactions between newly synthesized ruthenium complexes and cytokines in human colon carcinoma cell lines.

  1992cites this paper
• Antitumor activity of some ruthenium derivatives in human colon cancer cell lines in vitro.

  1992cites this paper
• New platinum, titanium, and ruthenium complexes with different patterns of DNA damage in rat ovarian tumor cells.

  1991cites this paper
• Metal Complexes as Antitumour Agents

  1990cites this paper
• New tumor-inhibiting metal complexes.

  1990cites this paper